Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.58 |
| ▸ | GCGR | P47871 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6752468 | 1.00 | MAPK14 (0.59) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL1387279 | 0.80 | MAPK14 (0.71) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL1387350 | 0.80 | MAPK14 (0.71) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL1387242 | 0.78 | MAPK14 (0.64) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL6749396 | 0.78 | MAPK14 (0.64) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL19864312 | 0.77 | MAPK14 (0.73) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL1387186 | 0.75 | MAPK14 (0.71) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL4477244 | 0.73 | MAPK14 (0.58) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL4467013 | 0.73 | MAPK14 (0.58) | MAPK14MAPK11MAPK13MAPK12GCGR | |
| SCHEMBL1387412 | 0.73 | MAPK14 (1.00) | MAPK14MAPK11MAPK13MAPK12GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2004-06-03 | — | — | US | disclosed |
| EP-1306377-A2 | Pyridyl-oxazoles and their use as cytokines inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-6288062-B1 | INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-11 | — | — | US | disclosed |
| EP-0727998-A4 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0727998-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013067-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | IL2, IL17A, IL5 | MAPK14 709/4885MAPK11 1534/4885MAPK13 1607/4885 |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | IL17A, IL4I1, IL2 | MAPK14 870/4885MAPK11 1434/4885MAPK13 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.